- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00003992
Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2
Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Cancer
Aperçu de l'étude
Statut
Les conditions
Description détaillée
OBJECTIVES:
I. Evaluate the safety of paclitaxel plus trastuzumab (Herceptin) followed by adjuvant chemotherapy in women with node positive stage II or IIIa breast cancer with HER2 overexpression.
II. Evaluate the safety of long term trastuzumab (Herceptin) in this patient population.
OUTLINE: This is a randomized study. Patients are stratified according to radiotherapy (none planned vs planned to breast or chest wall). Patients are randomized to one of two treatment arms.
ARM I: Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1. Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses. At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses. Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
ARM II: Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year. ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin). Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 200 patients (100 per treatment arm) will be accrued for this study within 1 year.
Type d'étude
Inscription (Réel)
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
-
Pretoria, Afrique du Sud, 0001
- Pretoria Academic Hospital
-
-
-
-
California
-
Palo Alto, California, États-Unis, 94304
- Veterans Affairs Medical Center - Palo Alto
-
Stanford, California, États-Unis, 94305-5408
- Stanford University Medical Center
-
-
Colorado
-
Denver, Colorado, États-Unis, 80209-5031
- CCOP - Colorado Cancer Research Program, Inc.
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Emory University Hospital - Atlanta
-
Decatur, Georgia, États-Unis, 30033
- Veterans Affairs Medical Center - Atlanta (Decatur)
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University
-
Chicago, Illinois, États-Unis, 60611
- Veterans Affairs Medical Center - Chicago (Lakeside)
-
Decatur, Illinois, États-Unis, 62526
- CCOP - Central Illinois
-
Evanston, Illinois, États-Unis, 60201
- CCOP - Evanston
-
Peoria, Illinois, États-Unis, 61602
- CCOP - Illinois Oncology Research Association
-
Urbana, Illinois, États-Unis, 61801
- CCOP - Carle Cancer Center
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Veterans Affairs Medical Center - Indianapolis (Roudebush)
-
-
Iowa
-
Cedar Rapids, Iowa, États-Unis, 52403-1206
- CCOP - Cedar Rapids Oncology Project
-
-
Kansas
-
Wichita, Kansas, États-Unis, 67214-3882
- CCOP - Wichita
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- CCOP - Ochsner
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21231
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, États-Unis, 02111
- New England Medical Center Hospital
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- CCOP - Ann Arbor Regional
-
Kalamazoo, Michigan, États-Unis, 49007-3731
- CCOP - Kalamazoo
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Mayo Clinic Cancer Center
-
Saint Louis Park, Minnesota, États-Unis, 55416
- CCOP - Metro-Minnesota
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68131
- CCOP - Missouri Valley Cancer Consortium
-
-
New Jersey
-
Elizabeth, New Jersey, États-Unis, 07201
- Trinitas Hospital - Jersey Street Campus
-
Flemington, New Jersey, États-Unis, 08822
- Hunterdon Regional Cancer Program
-
Hackensack, New Jersey, États-Unis, 07601
- Hackensack University Medical Center
-
Hackensack, New Jersey, États-Unis, 07601
- CCOP - Northern New Jersey
-
Morristown, New Jersey, États-Unis, 07962-1956
- Morristown Memorial Hospital
-
-
New York
-
Albany, New York, États-Unis, 12208
- Veterans Affairs Medical Center - Albany
-
Bronx, New York, États-Unis, 10461
- Albert Einstein Comprehensive Cancer Center
-
New York, New York, États-Unis, 10016
- Kaplan Cancer Center
-
New York, New York, États-Unis, 10010
- Veterans Affairs Medical Center - New York
-
Rochester, New York, États-Unis, 14642
- University of Rochester Cancer Center
-
-
North Dakota
-
Fargo, North Dakota, États-Unis, 58122
- CCOP - Merit Care Hospital
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106-5065
- Ireland Cancer Center
-
-
Oklahoma
-
Tulsa, Oklahoma, États-Unis, 74136
- CCOP - Sooner State
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- University of Pennsylvania Cancer Center
-
Wynnewood, Pennsylvania, États-Unis, 19096
- CCOP - MainLine Health
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232-6838
- Vanderbilt Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53705
- Veterans Affairs Medical Center - Madison
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Comprehensive Cancer Center
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53295
- Veterans Affairs Medical Center - Milwaukee (Zablocki)
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
DISEASE CHARACTERISTICS:
- Histologically confirmed stage II or IIIa (T1-T3, N1-N2, M0) adenocarcinoma of the breast HER2 overexpression (2-3+ by immunochemistry)
- Bilateral breast cancer allowed
- Must have had local breast cancer surgery within past 12 weeks
- Mastectomy or lumpectomy with clear surgical margins AND axillary lymph node dissection with at least 6 nodes removed
- Hormone receptor status: Not specified
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Sex: Female
- WBC at least 3,000/mm3
- Platelet count at least 100,000/mm3
- Hemoglobin at least 9 g/dL
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- Creatinine no greater than 1.5 times ULN
- LVEF at least 50%
- No history of congestive cardiomyopathy
- No congestive heart failure or myocardial infarction within the past 6 months
- No uncontrolled hypertension
- No uncontrolled arrhythmia within the past 6 months
- No other prior malignancy within the past 5 years except curatively treated basal or squamous cell skin cancer or carcinoma in situ of the cervix
- No other serious medical illness that would limit survival to less than 2 years
- No psychiatric condition precluding study
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- No prior chemotherapy for breast cancer
- No prior hormonal therapy for breast cancer
- At least one year since prior tamoxifen for chemoprevention (e.g., Breast Cancer Prevention Trial)
- No prior radiotherapy to the breast, chest wall, or regional lymph nodes
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Arm I
Patients receive paclitaxel IV over 3 hours immediately followed by trastuzumab (Herceptin) IV over 30-90 minutes on day 1.
Paclitaxel repeats every 3 weeks for 4 courses and trastuzumab (Herceptin) repeats weekly for 10 courses.
At 3 weeks following paclitaxel and trastuzumab (Herceptin), patients receive doxorubicin IV and cyclophosphamide IV over 1 hour every 3 weeks for 4 courses.
Following chemotherapy, estrogen receptor (ER) positive and/or progesterone receptor (PR) positive patients receive oral tamoxifen twice daily for 5 years.
|
|
Expérimental: Arm II
Patients receive same therapy as in Arm I, except for additional trastuzumab (Herceptin) IV weekly beginning within 3 weeks following completion of chemotherapy and local therapy and continuing for 1 year.
ER and/or PR positive patients receive tamoxifen as in Arm I but may be concurrent with trastuzumab (Herceptin).
Following completion of doxorubicin and cyclophosphamide, post lumpectomy and post mastectomy patients may receive local radiotherapy daily for 5-6 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Sledge GW, O'Neill A, Thor A, et al.: Adjuvant trastuzumab: long-term results of E2198. [Abstract] Breast Cancer Res Treat 100 (Suppl 1): A-2075, S106, 2006.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies de la peau
- Tumeurs
- Tumeurs par site
- Maladies du sein
- Tumeurs mammaires
- Effets physiologiques des médicaments
- Mécanismes moléculaires de l'action pharmacologique
- Inhibiteurs d'enzymes
- Agents antirhumatismaux
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Modulateurs de tubuline
- Agents antimitotiques
- Modulateurs de mitose
- Hormones, substituts hormonaux et antagonistes hormonaux
- Agents antinéoplasiques, hormonaux
- Agents antinéoplasiques, alkylants
- Agents d'alkylation
- Agonistes myéloablatifs
- Agents antinéoplasiques phytogéniques
- Inhibiteurs de la topoisomérase II
- Inhibiteurs de la topoisomérase
- Agents antinéoplasiques immunologiques
- Antibiotiques, Antinéoplasiques
- Antagonistes hormonaux
- Agents de conservation de la densité osseuse
- Antagonistes des œstrogènes
- Modulateurs sélectifs des récepteurs aux œstrogènes
- Modulateurs des récepteurs aux œstrogènes
- Cyclophosphamide
- Paclitaxel
- Trastuzumab
- Doxorubicine
- Doxorubicine liposomale
- Tamoxifène
Autres numéros d'identification d'étude
- NCI-2012-02305
- E-2198
- CDR0000067197 (Identificateur de registre: PDQ (Physician Data Query))
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer du sein
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie